Eficacia de los probióticos en el control del Helicobacter Pylori

Anthony Sebastian Guzmán Labanda, Emily Mayte Cango Piedra, Carina Alexandra Serpa Andrade

Resumen


Introducción: Helicobacter pylori, bacteria micro aeróbica gramnegativa que no forma parte del microbioma intestinal, impacta a la mayoría de la población con una incidencia de 4,4 billones a nivel mundial, fue incluida en el 2017 como bacteria resistente a los antibióticos, por tal razón se busca implementar el uso de probióticos los cuales confiere beneficios en la salud del huésped.

Objetivo: Identificar la efectividad de los probióticos en el control del Helicobacter pylori, mediante la búsqueda de estudios científicos de los últimos 5 años, para la actualización del personal de salud. 

Métodos: Estudio descriptivo retrospectivo y observacional referente a la eficacia de los probióticos en el control de H. Pylori. Para la recopilación de información, bases de datos confiables como PubMed, LILACS y Scielo fueron utilizadas, mediante la búsqueda de descriptores MeSh y DeSC junto con operadores booleanos; se utilizó la siguiente ecuación: Helicobacter pylori and probióticos or antibióticos and erradicación.

Conclusiones: Los probióticos mejoran la tasa de erradicación y disminución de los efectos adversos siempre que sean utilizados junto con el tratamiento antibiótico. Saccharomices boulardii, (S. Boulardii) y Lactobacillus reuteri (L.reuteri) son las cepas probióticas a elección que demuestran mejores resultados en la tasa de erradicación con 94,2% y 92% respectivamente. Para que la terapia con antibióticos genere una mejora gastrointestinal, aumente la tasa de erradicación y alivie los síntomas clínicos se la debe implementar durante 14 días.


Palabras clave


Helicobacter pylori; probióticos; erradicación de la enfermedad; tratamiento.

Texto completo:

PDF HTML

Referencias


Bai, X., Zhu, M., He, Y., Wang, T., Tian, D., & Shu, J. (2022). The impacts of probiotics in eradication therapy of Helicobacter pylori. Archives of Microbiology, 204(12), 692. https://doi.org/10.1007/s00203-022-03314-w

Bustos-Fraga, S., Salinas-Pinta, M., Vicuña-Almeida, Y., de Oliveira, R. B., & Baldeón-Rojas, L. (2023). Prevalence of Helicobacter pylori genotypes: cagA, vacA (m1), vacA (s1), babA2, dupA, iceA1, oipA and their association with gastrointestinal diseases. A cross-sectional study in Quito-Ecuador. BMC Gastroenterology, 23(1), 197. https://doi.org/10.1186/s12876-023-02838-9

Chen, L., Xu, W., Lee, A., He, J., Huang, B., Zheng, W., Su, T., Lai, S., Long, Y., Chu, H., Chen, Y., Wang, L., Wang, K., Si, J., & Chen, S. (2018). The impact of Helicobacter pylori infection, eradication therapy and probiotic supplementation on gut microenvironment homeostasis: An open-label, randomized clinical trial. EBioMedicine, 35, 87–96. https://doi.org/10.1016/j.ebiom.2018.08.028

He, C., Xie, Y., Zhu, Y., Zhuang, K., Huo, L., Yu, Y., Guo, Q., Shu, X., Xiong, Z., Zhang, Z., Lyu, B., & Lu, N. (2022). Probiotics modulate gastrointestinal microbiota after Helicobacter pylori eradication: A multicenter randomized double-blind placebo-controlled trial. Frontiers in Immunology, 13. https://doi.org/10.3389/fimmu.2022.1033063

Ho, J. J. C., Navarro, M., Sawyer, K., Elfanagely, Y., & Moss, S. F. (2022). Helicobacter pylori Antibiotic Resistance in the United States Between 2011 and 2021: A Systematic Review and Meta-Analysis. American Journal of Gastroenterology, 117(8), 1221–1230. https://doi.org/10.14309/ajg.0000000000001828

Ji, J., & Yang, H. (2020). Using Probiotics as Supplementation for Helicobacter pylori Antibiotic Therapy. International Journal of Molecular Sciences, 21(3), 1136. https://doi.org/10.3390/ijms21031136

Kamiya, S., Yonezawa, H., & Osaki, T. (2019). Role of Probiotics in Eradication Therapy for Helicobacter pylori Infection (pp. 243–255). https://doi.org/10.1007/5584_2019_369

Koga, Y. (2022). Microbiota in the stomach and application of probiotics to gastroduodenal diseases. World Journal of Gastroenterology, 28(47), 6702–6715. https://doi.org/10.3748/wjg.v28.i47.6702

Liang, B., Yuan, Y., Peng, X.-J., Liu, X.-L., Hu, X.-K., & Xing, D.-M. (2022b). Current and future perspectives for Helicobacter pylori treatment and management: From antibiotics to probiotics. Frontiers in Cellular and Infection Microbiology, 12. https://doi.org/10.3389/fcimb.2022.1042070

Li, M., Wang, X., Dong, X., Teng, G., Dai, Y., & Wang, W. (2024). Lactobacillus reuteri compared with placebo as an adjuvant in Helicobacter pylori eradication therapy: a meta-analysis of randomized controlled trials. Therapeutic Advances in Gastroenterology, 17. https://doi.org/10.1177/17562848241258021

McNicholl, A. G., Molina‐Infante, J., Lucendo, A. J., Calleja, J. L., Pérez‐Aisa, Á., Modolell, I., Aldeguer, X., Calafat, M., Comino, L., Ramas, M., Callejo, Á., Badiola, C., Serra, J., & Gisbert, J. P. (2018). Probiotic supplementation with Lactobacillus plantarum and Pediococcus acidilactici for Helicobacter pylori therapy: A randomized, double‐blind, placebo‐controlled trial. Helicobacter, 23(5). https://doi.org/10.1111/hel.12529

Moreno Márquez, C., Fernández Álvarez, P., Valdés Delgado, T., Castro Laria, L., Argüelles Arias, F., Caunedo Álvarez, A., & Gómez Rodríguez, B. J. (2021). Randomized, double-blind, placebo-controlled clinical trial on the usefulness of probiotic Lactobacillus reuteri in bismuth-containing quadruple eradication therapy for infection with Helicobacter pylori. Revista Española de Enfermedades Digestivas. https://doi.org/10.17235/reed.2021.7931/2021

Naghibzadeh, N., Salmani, F., Nomiri, S., & Tavakoli, T. (2022). Investigating the effect of quadruple therapy with Saccharomyces boulardii or Lactobacillus reuteri strain (DSMZ 17648) supplements on eradication of Helicobacter pylori and treatments adverse effects: a double-blind placebo-controlled randomized clinical trial. BMC Gastroenterology, 22(1), 107. https://doi.org/10.1186/s12876-022-02187-z

Pohl, D., Keller, P. M., Bordier, V., & Wagner, K. (2019). Review of current diagnostic methods and advances in Helicobacter pylori diagnostics in the era of next generation sequencing. World Journal of Gastroenterology, 25(32), 4629–4660. https://doi.org/10.3748/wjg.v25.i32.4629

Rokkas, T., Gisbert, J. P., Malfertheiner, P., Niv, Y., Gasbarrini, A., Leja, M., Megraud, F., O’Morain, C., & Graham, D. Y. (2021). Comparative Effectiveness of Multiple Different First-Line Treatment Regimens for Helicobacter pylori Infection: A Network Meta-analysis. Gastroenterology, 161(2), 495-507.e4. https://doi.org/10.1053/j.gastro.2021.04.012

Shi, X., Zhang, J., Mo, L., Shi, J., Qin, M., & Huang, X. (2019). Efficacy and safety of probiotics in eradicating Helicobacter pylori. Medicine, 98(15), e15180. https://doi.org/10.1097/MD.0000000000015180

Šterbenc, A., Jarc, E., Poljak, M., & Homan, M. (2019). Helicobacter pylori virulence genes. World Journal of Gastroenterology, 25(33), 4870–4884. https://doi.org/10.3748/wjg.v25.i33.4870

Sun, Y., & Zhang, J. (2019). Helicobacter pylori recrudescence and its influencing factors. Journal of Cellular and Molecular Medicine, 23(12), 7919–7925. https://doi.org/10.1111/jcmm.14682

Suzuki, S., Esaki, M., Kusano, C., Ikehara, H., & Gotoda, T. (2019). Development of Helicobacter pylori treatment: How do we manage antimicrobial resistance? World Journal of Gastroenterology, 25(16), 1907–1912. https://doi.org/10.3748/wjg.v25.i16.1907

TONG, J. L., RAN, Z. H., SHEN, J., ZHANG, C. X., & XIAO, S. D. (2020). Meta‐analysis: the effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy. Alimentary Pharmacology & Therapeutics, 25(2), 155–168. https://doi.org/10.1111/j.1365-2036.2006.03179.x

Tshibangu-Kabamba, E., & Yamaoka, Y. (2021). Helicobacter pylori infection and antibiotic resistance — from biology to clinical implications. Nature Reviews Gastroenterology & Hepatology, 18(9), 613–629. https://doi.org/10.1038/s41575-021-00449-x

Viazis, N., Argyriou, K., Kotzampassi, K., Christodoulou, D. K., Apostolopoulos, P., Georgopoulos, S. D., Liatsos, C., Giouleme, O., Koustenis, K., Veretanos, C., Stogiannou, D., Moutzoukis, M., Poutakidis, C., Mylonas, I. I., Tseti, I., & Mantzaris, G. J. (2022). A Four-Probiotics Regimen Combined with A Standard Helicobacter pylori-Eradication Treatment Reduces Side Effects and Increases Eradication Rates. Nutrients, 14(3), 632. https://doi.org/10.3390/nu14030632

Villavicencio Saque, R., Sánchez Pérez, G., Chávez Cruz, C., Loza Munarriz, C., & Espinoza Ríos, J. (2022). [Antibiotic resistance of Helicobacter pylori in the Peruvian population: a systematic review and meta-analysis of its prevalence in the general population]. Revista de Gastroenterologia Del Peru : Organo Oficial de La Sociedad de Gastroenterologia Del Peru, 42(3), 151–162.

Wieërs, G., Belkhir, L., Enaud, R., Leclercq, S., Philippart de Foy, J.-M., Dequenne, I., de Timary, P., & Cani, P. D. (2020). How Probiotics Affect the Microbiota. Frontiers in Cellular and Infection Microbiology, 9. https://doi.org/10.3389/fcimb.2019.00454

Xu, W., Xu, L., & Xu, C. (2022). Relationship between Helicobacter pylori infection and gastrointestinal microecology. Frontiers in Cellular and Infection Microbiology, 12. https://doi.org/10.3389/fcimb.2022.938608

Xu, X., He, C., & Zhu, Y. (2022). Treatment of refractory Helicobacter pylori infection: A new challenge for clinicians. Frontiers in Microbiology, 13. https://doi.org/10.3389/fmicb.2022.998240

Yang, C., Liang, L., Lv, P., Liu, L., Wang, S., Wang, Z., & Chen, Y. (2021). Effects of non‐viable Lactobacillus reuteri combining with 14‐day standard triple therapy on Helicobacter pylori eradication: A randomized double‐blind placebo‐controlled trial. Helicobacter, 26(6). https://doi.org/10.1111/hel.12856

Yuan, Z., Xiao, S., Li, S., Suo, B., Wang, Y., Meng, L., Liu, Z., Yin, Z., Xue, Y., & Zhou, L. (2021). The impact of Helicobacter pylori infection, eradication therapy, and probiotics intervention on gastric microbiota in young adults. Helicobacter, 26(6). https://doi.org/10.1111/hel.12848

Zamani, M., Ebrahimtabar, F., Zamani, V., Miller, W. H., Alizadeh‐Navaei, R., Shokri‐Shirvani, J., & Derakhshan, M. H. (2018). Systematic review with meta‐analysis: the worldwide prevalence of Helicobacter pylori infection. Alimentary Pharmacology & Therapeutics, 47(7), 868–876. https://doi.org/10.1111/apt.14561




DOI: https://doi.org/10.23857/pc.v9i8.7739

Enlaces de Referencia

  • Por el momento, no existen enlaces de referencia
';

Bookmark and Share




Polo del Conocimiento              

Revista Científico-Académica Multidisciplinaria

ISSN: 2550-682X

Casa Editora del Polo                                                 

Manta - Ecuador       

Dirección: Ciudadela El Palmar, II Etapa,  Manta - Manabí - Ecuador.

Código Postal: 130801

Teléfonos: 056051775/0991871420

Email: polodelconocimientorevista@gmail.com / director@polodelconocimiento.com

URL: https://www.polodelconocimiento.com/